Statistical Issues Arising in AIDS Clinical Trials

By Ellenberg, Susan S.; Finkelstein, Dianne M. et al. | Journal of the American Statistical Association, June 1992 | Go to article overview

Statistical Issues Arising in AIDS Clinical Trials


Ellenberg, Susan S., Finkelstein, Dianne M., Schoenfeld, David A., Journal of the American Statistical Association


The evaluation of treatments for the acquired immune deficiency syndrome (AIDS) and human immunodeficiency virus (HIV)-related disorders has become a large-scale effort in a very short period. AIDS as a disease entity was first noted in 1981, when the Centers for Disease Control (CDC) reported rare forms of pneumonia and skin cancer in young gay men in California and New York (CDC 1981 a). The first "definition" of AIDS, developed by the CDC (1982), appeared in 1982. The virus was isolated in 1983 (Barre-Sinoussi et al. 1983), and tests for the disease-documenting antibodies became available the following year. These developments led to a revised CDC definition of AIDS to include a positive antibody test and a more detailed description of the clinical events (primarily opportunistic infections and malignancies) that formed the syndrome.

The identification and isolation of HIV permitted the initiation of drug development efforts. In 1986 funds were first awarded by the National Institute of Allergy and Infectious Diseases (NIAID) for a national cooperative clinical trials program modeled loosely on the oncology cooperative group model developed at the National Cancer Institute (NCI). The efforts to find a treatment produced the first effective drug, zidovudine (ZDV or AZT), in a surprisingly brief period; The results of a highly positive randomized placebo-controlled trial of AZT were published early in 1987 (Fischl et al. 1987), and the drug was approved for marketing by the Food and Drug Administration (FDA) shortly thereafter.

AIDS is different from other life-threatening diseases for which treatments are routinely studied in clinical trials. First, it is an epidemic. AIDS is an infectious disease for which a substantial proportion of the population is at risk. This circumstance provokes a different mind-set than that associated with other frequently fatal diseases, such as cancer, that affect far greater numbers of individuals. This infectious disease, however, is also a chronic illness. The sense of urgency engendered by the concept of an epidemic is therefore directly confronted with all the complications and delays inherent in studying a chronic disease with survival time as a primary outcome of concern.

Second, AIDS is a new disease. Our understanding of the natural history is growing rapidly, but is still very limited compared to diseases that we have been studying for decades or even centuries. The disease is complicated, with large numbers of potentially fatal sequelae, each of which may require a different therapeutic and/or prophylactic approach. Each new effective regimen itself alters the "natural history"; our success in reducing the incidence of any of these infections results in an increased incidence of other opportunistic diseases.

Finally, the nature of the populations that have borne the brunt of the epidemic is unusual. At least in the United States, AIDS is a disease of homosexuals, of intravenous drug users, of minorities, and of the poor--all groups that are stigmatized to varying degrees by "mainstream" society. Because some of these groups are virtually removed from the health care system, it is difficult to involve them in studies of investigational drugs. The gay population, on the other hand, had become highly politicized over civil rights issues even before AIDS; the advent of the disease has heightened their concerns substantially. Representatives of affected communities have become increasingly vocal regarding issues related to testing of investigational drugs (Harrington 1990; Ellenberg et al., in press).

All these issues generate intense and often conflicting concerns for statisticians designing clinical trials to evaluate AIDS therapies. The development of more efficient clinical trials designs long has been a research topic of interest to statisticians, and the impact of the pertinent issues on trial designs have been discussed by Byar et al. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Statistical Issues Arising in AIDS Clinical Trials
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.